Equities research analysts forecast that MorphoSys AG Unsponsored ADR (NYSE:MOR) will announce sales of $10.34 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for MorphoSys’ earnings. The highest sales estimate is $10.51 million and the lowest is $10.17 million. MorphoSys reported sales of $3.44 million in the same quarter last year, which suggests a positive year over year growth rate of 200.6%. The business is scheduled to report its next quarterly earnings report on Wednesday, May 1st.
On average, analysts expect that MorphoSys will report full year sales of $65.67 million for the current fiscal year, with estimates ranging from $53.11 million to $78.54 million. For the next financial year, analysts anticipate that the company will report sales of $154.40 million, with estimates ranging from $90.40 million to $194.94 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for MorphoSys.
Separately, Leerink Swann reiterated an “outperform” rating on shares of MorphoSys in a report on Friday, January 11th.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Article: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.